BioNeutral Group Retains Michael D. Cress and MD Cress & Associates, a National Healthcare Advisory Firm

Michael Cress to Advise BioNeutral on Effective Business Optimization in the Hospital and Healthcare Arena

Dec 01, 2010, 07:00 ET from BioNeutral Group, Inc.

NEWARK, N.J., Dec. 1, 2010 /PRNewswire-FirstCall/ -- BioNeutral Group Inc, (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced it is working with Michael Cress and his highly specialized team to navigate the rapidly changing healthcare industry.

Mr. Cress is a seasoned senior executive with over 30 years of experience in the areas of executive leadership, operations, clinical medical practice, and business development. He serves as Chairman and CEO of MD Cress & Associates, LLC, a national healthcare advisory firm that focuses on constructing effective business optimization, growth and acquisition strategies that support and expand key business objectives for organizations. MD Cress's team of experts provides the domain expertise and business knowledge to enable BioNeutral to focus on constructing an effective growth strategy in hospitals, nursing homes, rehabilitation, and other segments of the healthcare industry.

Mr. Cress said, "It's been a pleasure getting to know BioNeutral and its Management Team over the past several weeks.  Based on my discussions and review of the independent research data, I believe that BioNeutral has a product platform that can potentially set the new standard for how cleaning and sterilization is handled across the healthcare continuum."

Prior to MD Cress & Associates, LLC Mr. Cress served as the President and CEO of the Cornerstone Healthcare Group which owns and manages hospitals throughout the country.

Mr. Cress also served as Vice President of Business Development for Kindred Healthcare, a $4 billion publicly traded healthcare company that owns and operates hospitals, nursing homes, rehabilitation, pharmacy and other segments of the healthcare continuum. He served as the CEO of Vencor Hospital of San Diego and was also an Adjunct Professor for the Masters of Healthcare Administration program at the University of Kansas.

Mr. Cress is an advisor to several companies to include Linley Capital, an international private investment firm based in NYC and the Stiefel Nicolaus healthcare research group based in Baltimore MD and serves on several boards to include Lift Up America, Rachel's Challenge, KAS Consulting, Little Helping Hands, Texas CEO Magazine and Trusted Care Network. He is published and has been a national speaker on numerous healthcare business and clinical topics.

Dr. Andy Kielbania, Chief Scientist of BioNeutral Group, stated, "The healthcare arena is a major focus for us with our complete product line. Understanding how and why this market segment makes purchase decisions is key to how we position our products. I believe that MD Cress Associates will provide us with the required understanding and pathway forward for the healthcare market."

About MD Cress and Associates LLC

MD Cress & Associates is a national healthcare advisory firm that focuses on constructing effective business optimization, growth and acquisition strategies that support and expand key business objectives for organizations.

The experienced professionals at MD Cress & Associates work hand-in-hand with executives to evaluate the performance of their organizations and identify opportunities to drive future growth and deliver significant gains in operational efficiency.   They combine extensive industry, operations, strategy and transaction experience to rapidly deliver significant value-add to our clients.  At MD Cress & Associates, their client-first approach enables business owners and executives to maximize returns on invested capital, achieve corporate objectives and enhance shareholder value.

For more information on M.D. Cress and Associates LLC, please see www.mdcress.com  

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace.  BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

SOURCE BioNeutral Group, Inc.



RELATED LINKS

http://www.bioneutralgroup.com/